These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12616491)

  • 1. Artificial-infection protocols allow immunodetection of novel Borrelia burgdorferi antigens suitable as vaccine candidates against Lyme disease.
    Wallich R; Jahraus O; Stehle T; Tran TT; Brenner C; Hofmann H; Gern L; Simon MM
    Eur J Immunol; 2003 Mar; 33(3):708-19. PubMed ID: 12616491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of Borrelia burgdorferi gene expression in naturally (tick) infected mouse strains.
    Lederer S; Brenner C; Stehle T; Gern L; Wallich R; Simon MM
    Med Microbiol Immunol; 2005 Jan; 194(1-2):81-90. PubMed ID: 15112080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmid DNA and protein vaccination of mice to the outer surface protein A of Borrelia burgdorferi leads to induction of T helper cells with specificity for a major epitope and augmentation of protective IgG antibodies in vivo.
    Zhong W; Wiesmüller KH; Kramer MD; Wallich R; Simon MM
    Eur J Immunol; 1996 Nov; 26(11):2749-57. PubMed ID: 8921965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
    Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
    Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Borrelia burgdorferi outer surface protein (osp) B expression independent of ospA.
    Liang FT; Caimano MJ; Radolf JD; Fikrig E
    Microb Pathog; 2004 Jul; 37(1):35-40. PubMed ID: 15194158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
    Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
    J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A recombinant vaccine for Lyme disease.
    Wallich R; Kramer MD; Simon MM
    Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Borrelia burgdorferi strain 25015: characterization of outer surface protein A and vaccination against infection.
    Fikrig E; Barthold SW; Persing DH; Sun X; Kantor FS; Flavell RA
    J Immunol; 1992 Apr; 148(7):2256-60. PubMed ID: 1545130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice.
    Bockenstedt LK; Fikrig E; Barthold SW; Flavell RA; Kantor FS
    J Immunol; 1996 Dec; 157(12):5496-502. PubMed ID: 8955199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula.
    Nassal M; Skamel C; Kratz PA; Wallich R; Stehle T; Simon MM
    Eur J Immunol; 2005 Feb; 35(2):655-65. PubMed ID: 15668917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines.
    Nassal M; Skamel C; Vogel M; Kratz PA; Stehle T; Wallich R; Simon MM
    Int J Med Microbiol; 2008 Jan; 298(1-2):135-42. PubMed ID: 17888729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
    Molloy PJ; Berardi VP; Persing DH; Sigal LH
    Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant outer surface protein a from Borrelia burgdorferi induces antibodies protective against spirochetal infection in mice.
    Simon MM; Schaible UE; Kramer MD; Eckerskorn C; Museteanu C; Müller-Hermelink HK; Wallich R
    J Infect Dis; 1991 Jul; 164(1):123-32. PubMed ID: 1829104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization of mice by recombinant OspA preparations and protection against Borrelia burgdorferi infection induced by Ixodes ricinus tick bites.
    Gern L; Rais O; Capiau C; Hauser P; Lobet Y; Simoen E; Voet P; Pêtre J
    Immunol Lett; 1994 Mar; 39(3):249-58. PubMed ID: 8034340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mouse model for Borrelia burgdorferi infection: pathogenesis, immune response and protection.
    Schaible UE; Wallich R; Kramer MD; Museteanu C; Simon MM
    Behring Inst Mitt; 1991 Feb; (88):59-67. PubMed ID: 2049047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lyme borreliosis vaccination: the facts, the challenge, the future.
    Schuijt TJ; Hovius JW; van der Poll T; van Dam AP; Fikrig E
    Trends Parasitol; 2011 Jan; 27(1):40-7. PubMed ID: 20594913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains.
    Earnhart CG; Buckles EL; Marconi RT
    Vaccine; 2007 Jan; 25(3):466-80. PubMed ID: 16996663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunochemical analysis of the immune response in late manifestations of Lyme borreliosis].
    Wilske B; Preac-Mursic V; Schierz G; Gueye W; Herzer P; Weber K
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Mar; 267(4):549-58. PubMed ID: 3381603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC.
    Zhong W; Gern L; Stehle T; Museteanu C; Kramer M; Wallich R; Simon MM
    Eur J Immunol; 1999 Mar; 29(3):946-57. PubMed ID: 10092099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.